The Global Drug sales of Remicade stood at USD 2,550 Millions in 2022
The indicator recorded a historical decline (CAGR) of22% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Infliximab (Remicade) is a chimeric IgG1 monoclonal antibody specific for human tumor necrosis factor-alpha (TNFa). Infliximab is manufactured by a recombinant cell line cultured by continuous perfusion. It is formulated as injectable powder for solution for intravenous route of administration.
Mechanism of Action
Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFß (lymphotoxin-a), a related cytokine that utilizes the same receptors as TNFa. Biological activities attributed to TNFa include: induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil and eosinophil functional activity, induction of acute phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab inhibits the functional activity of TNFa in a wide variety of in vitro bioassays utilizing human fibroblasts, endothelial cells, neutrophils, B and T- lymphocytes and epithelial cells.
Remicade Overview
Remicade is marketed for the treatment of several indications in Cardiovascular, Dermatology, Gastrointestinal, Immunology, Musculoskeletal Disorders, and Oncology therapy areas.
Remicade is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, for reducing signs and symptoms and inducing and maintai ning clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticoste roid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis, for reducing signs and s ymptoms in patients with active ankylosing spondylitis, for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoria tic arthritis, or the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
Remicade was first approved in 1998 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Schering-Plough Corp, Mitsubishi Chemical Holdings Corp, Merck & Co Inc, and Johnson & Johnson. Remicade drug sales recorded a low-double digit Year on Year decline in 2022. Remicade drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward